GAIL BOLAN, M. D.; CLAIRE V. BROOME, M.D.; RICHARD R. FACKLAM, Ph.D; BRIAN D. PLIKAYTIS, M.S.; DAVID W. FRASER, M.D.; WALTER F. SCHLECH III, M.D.
The efficacy of pneumococcal vaccine in groups of patients in the United States at high risk for pneumococcal disease was estimated by comparing distributions of serotypes of Streptococcus pneumoniae isolated from vaccinated and unvaccinated persons. Between May 1978 and March 1984, 187 blood isolates and 62 cerebrospinal fluid isolates from vaccinated patients, and 1447 blood isolates and 191 cerebrospinal fluid isolates from unvaccinated patients were serotyped at the Centers for Disease Control. The study did not include patients who were less than 2 years old or who had Hodgkin's disease, multiple myeloma, or immunoglobulin deficiency. In patients with bacteremic disease, the overall efficacy of pneumococcal vaccine was estimated at 64% (95% confidence limits, 47% to 76%); efficacy did not differ significantly with age. In persons over 65 years of age with diabetes mellitus, chronic heart disease, pulmonary disease, or no underlying illnesses, efficacy was 61% (95% confidence limits, 1% to 85%). These findings support the use of pneumococcal vaccine in selected populations in the United States.
BOLAN G, BROOME CV, FACKLAM RR, PLIKAYTIS BD, FRASER DW, SCHLECH WF. Pneumococcal Vaccine Efficacy in Selected Populations in the United States. Ann Intern Med. ;104:1–6. doi: 10.7326/0003-4819-104-1-1
Download citation file:
Published: Ann Intern Med. 1986;104(1):1-6.
Infectious Disease, Prevention/Screening, Streptococcal Infections, Vaccines/Immunization.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use